US
Surgeon General calls for cultural shift in approach to opioid crisis
September 21, 2018Medical Communications Trump, US, opioid crisis, opioid epidemic, surgeon general
The Surgeon General of the United States has called for a cultural shift in the way in which Americans talk …
Senate bill would save money and allow generics to reach market more quickly, according to CBO report
September 20, 2018Business Services, Medical Communications, Sales and Marketing CBO, Senate, US, biosimilars, generics, law, politics
The Congressional Budget Office (CBO) has said in a report that a bipartisan bill awaiting a vote in the senate …
FDA greenlights Teva’s migraine drug Ajovy in two dosage options
September 20, 2018Sales and Marketing FDA, Teva, US, ajovy, migraine, pharma
Israeli drugmaker Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (remanezumab-vfrm) has received FDA approval as a …
US Senate pass bipartisan bill to tackle opioid crisis
September 18, 2018Manufacturing and Production Senate, US, epidemic, opioid, opioid crisis, politics
The US Senate have passed a bipartisan bill aimed at combatting the opioid crisis. The bill, which was passed with …
Teva shares soar after migraine treatment Ajovy approval
September 17, 2018Sales and Marketing FDA, Teva, US, ajovy, approval, israel
Shares in the Israeli pharma firm Teva soared on Sunday after the announcement that the US Food and Drug Administration …
GSK’s Nucala data insufficient for US COPD approval
September 10, 2018Sales and Marketing COPD, FDA, GSK, Nucala, US, pharma
GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …
FDA recruitment official says Trump’s policies are making hiring difficult
September 7, 2018Medical Communications FDA, Trump, US, hiring, recruitment
Melanie Keller, Acting Associate Commissioner for Scientific and Clinical Recruitment at the US Food and Drug Administration (FDA) has said …
Trump administration resists WHO efforts to tackle antimicrobial resistance
August 31, 2018Medical Communications AMR, Trump, US, US government, WHO, antimicrobial resistance
The Trump administration is in the process of drafting an alternative to the World Health Organization’s guidelines on the use …
Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration
August 20, 2018Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma
Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the …
FDA approves first-ever generic EpiPen versions, courtesy of Teva
August 17, 2018Medical Communications, Sales and Marketing FDA, Mylan, Teva, US, epipen, pharma
The FDA has announced the approval of the first generic versions of Mylan’s EpiPen and EpiPen Jr epinephrine auto-injectors as …
Indicted GOP congressman Chris Collins’ terminates re-election campaign
August 13, 2018Medical Communications, Sales and Marketing Chris Collins, Innate Therapeutics, US, pharma
Indicted republican congressman Chris Collins has performed a U-turn since his arrest on Wednesday under allegations of insider trading, confirming …
FDA approves first oral therapy for rare Fabry disease
August 13, 2018Sales and Marketing FDA, Fabry disease, US, pharma
Amicus has revealed that its therapy Galafold (migalastat) has been awarded approval by the FDA in the treatment of adult …
US Congressman arrested over insider trading in biopharma firm
August 9, 2018Research and Development, Sales and Marketing Chris Collins, Innate, Innate Immunotherapeutics, US, congress, multiple sclerosis, pharma
A Republican Congressman has been arrested by the FBI over on charges of insider trading with shares in Australian biopharmaceutical …
FDA expands list of valsartan recalls
August 9, 2018Medical Communications China, FDA, US, heart medication, recall, valsartan
The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled. …
AstraZeneca to pay $110m to settle allegations of fraudulent marketing in Texas
August 8, 2018Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Texaas, US, pharma
AstraZeneca has backed down in a dispute with the State of Texas over allegations it had defrauded the state’s Medicaid …
Latest content
FibroFind appoints Lee Borthwick as CEO
